Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03291041 · ClinicalTrials.gov registry record · Phase 2
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
A Phase 2 study of Jet Lag Disorder, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT03291041 is a Phase 2 study of Jet Lag Disorder that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 25 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT03291041, a Phase 2 study of Jet Lag Disorder, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tasimelteon
Study Locations (3)
California
- Vanda Investigational Site - Alameda
- Vanda Investigational Site - Santa Monica
Maryland
- Vanda Investigational Site - Chevy Chase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03291041
The ClinicalTrials.gov registry entry for NCT03291041 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Jet Lag Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03291041 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.
Frequently Asked Questions
What is clinical trial NCT03291041 about?
NCT03291041 is a clinical study titled "A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder". A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
What is the current status of trial NCT03291041?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2016-07. Estimated completion is 2017-11.
What conditions does trial NCT03291041 study?
This clinical trial studies the following conditions: Jet Lag Disorder.
What interventions are being tested in trial NCT03291041?
The interventions under investigation include: Placebo (DRUG), Tasimelteon (DRUG).
Who is sponsoring clinical trial NCT03291041?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03291041 being conducted?
This trial has 3 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Jet Lag Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.